http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2173900-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_661b3ea63e73acc96731eb73625b1bc2 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2320-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-53 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-531 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-111 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-14 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-1131 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 |
| filingDate | 2008-06-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ef2cac928d7938ebc444d3bb4d29eac9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bd025309f1e45cdcf170d7a55134ca27 |
| publicationDate | 2010-04-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-2173900-A2 |
| titleOfInvention | Hepatitis c dsrna effector molecules, expression constructs, compositions, and methods of use |
| abstract | The present invention provides agents, compositions, constructs, and methods for attenuating HCV polynucleotides, as well as methods and compositions for treating a mammalian cell infected with hepatitis C virus or preventing it. In one aspect, the present invention provides an agent or composition comprising at least one effector molecule or a double stranded RNA effector complex. The effector molecule or the double stranded RNA effector complex comprises: (1) a sequence of at least 19 nucleotides having at least 90% identity with a nucleotide sequence within a conserved region 1 (SEQ ID N 2) HCV, a conserved region 2 (SEQ ID NO: 3) of HCV, a conserved region (SEQ ID NO: 4) of HCV, (ATR) -1 (SEQ ID NO: 86) (ATR) -2 (SEQ ID NO: 87), (ATR) -3 (SEQ ID NO: 88), (ATR) -4 (SEQ ID NO: 89); and (2) its complementary sequence. In another aspect, the present invention provides a construct suitable for replication in a host cell, and / or suitable for expression of an RNA molecule or complex of the invention in vitro or in vivo. According to a third aspect, the present invention provides a method for attenuating HCV RNA in a mammalian cell, which comprises administering to the mammalian cell an agent, composition or construct according to the invention, a and in an amount effective to attenuate HCV RNA in the cell. In a related aspect, the invention provides a method for treating a patient infected with the hepatitis C virus or preventing infection of a patient with the hepatitis C virus by administering to the patient a effective amount of an agent, composition or construction according to the invention as described herein. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-4035659-A1 |
| priorityDate | 2007-06-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 201.